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Summary 
The identification of the etiological factor of many cervical precancerous lesions and cervical cancer, the 
Human papillomavirus (HPV) is widely used. In this study, we evaluated the consensus and type-specific 
(TS) Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP), Line Probe 
Assay (LiPA, Innogenetics) and sequencing to determine the HPV types in cervical specimens. Out of 690 
High-grade Squamous Intraepithelial Lesion (HSIL) samples, 86.7% were HPV positive and 13.3% HPV 
negative by consensus primers (MY09/MY11, L1C1/L1C2-1/L1C2-2 and/or GP5/6) directed PCR. Out of 
598 HPV positive samples, 85.3% were typed by TS-PCR being HPV 6/11, 16, 18, 31 and/or 33, while 
14.7% remained untyped. The most prevalent HPV type in the study group was HPV 16, identified in 35.5% 
cases, while HPV 31 was the second most frequent HPV type with a prevalence of 10.5%. They were 
followed by HPV types 6/11, 33 and 18 with a prevalence of 7.4%, 6.2% and 4.9%, respectively. Multiple 
HPV infections with two or more HPV types (6/11, 16, 18, 31 and/or 33) were found in 9.4% cases. A 
subset of 88 samples was further typed by RFLP and LiPA to determine the rare HPV types in HSIL 
samples. The most frequent low abundant HPV types in single infections in decreasing order were HPV 53, 
58, 66, 56 and 52, while HPV 51 was the most frequent low abundant HPV type found in multiple HPV 
infections. Multiple HPV infections were mostly found by LiPA in 27.3% cases versus 14.8% cases found 
by RFLP. The perfect agreement between RFLP and LiPA assay pair was observed only for HPV types 16, 
18, 34 and 59 (Kappa value of 1). For other HPV types, the inter-assay agreement ranged from very good to 
no agreement indicating that neither assay is perfect. Sequencing was performed for 33 samples in cases 
where both RFLP and LiPA were inconclusive. Sequencing was shown to be a very good method in case of 
single HPV infection but not applicable in case of multiple HPV infections. Both RFLP and LiPA are good 
assays for epidemiological studies, although RFLP being cumbersome and time-consuming is less applicable 
than LiPA. Careful consideration has to be made before the implementation of either HPV typing methods in 
clinical laboratories.  
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Introduction 
Human papillomaviruses (HPV) have been recognized as an etiologic factor of a variety of 
widespread human cancers, anogenital and head and neck cancers.
1-3
 Until now, more than 100 HPV types 
have been identified and fully sequenced.
4
 Approximately 40 HPV types infect the anogenital tract and a 
few are found in anogenital cancer biopsy specimens, notably cervical cancer. Oncogenic HPVs have been 
identified in almost all cervical cancer biopsies, i.e. 99.7% cases,
5 
what makes them undoubtedly the cause 
of the disease. According to the last epidemiological classification, 15 HPV types: 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68, 73 and 82 are considered as highly oncogenic (high-risk [HR]), and HPV types 26, 53 
and 66 as probably oncogenic, while HPV types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108 are 
classified as viruses with low oncogenic potential (low-risk [LR]).
6
 HPV 16 and 18 alone are found in nearly 
60% and 17% of cervical cancer cases worldwide, respectively, while all other HPV types are found in less 
than 1-7% cases each.
7
 In addition, multiple HPV infections seem to be very common and in previous 
studies were found in almost 7% of women with precancerous cervical lesions.
8,9
 
Currently, DNA amplification mediated by the polymerase chain reaction (PCR) is the most specific 
and the most sensitive for revealing the presence of otherwise undetectable quantities of HPV DNA. Several 
methods for HPV typing by PCR were developed in research laboratories. The identification of HPV types 
may be accomplished either by Type-Specific (TS) based PCR (TS-PCR) or by analysis of consensus PCR 
products through hybridisation with TS probes fixed on solid support (i.e. nylon or nitrocellulose strips or 
chip), Restriction Fragment Length Polymorphism (RFLP) or sequencing.
10
 The TS-PCR
8,11,12
 is a useful 
tool for identification of individual HPV types, especially HR types, and it is a good approach if only a few 
types need to be identified. As at least 15 HR HPV types are important for epidemiological studies TS-PCR 
is not the best approach, because it is time consuming and not at all cost-effective for the determination of so 
many HPV types. It is why several group of researchers developed the line blot assays based on the 
hybridisation with specific probes fixed on strip and consensus HPV amplicons generated with different 
biotin-labelled primers: MY09/11/HMB01,
13
 SPF1/2,
14
 and GP5+/6+,
15
 allowing the detection of as much 
HPV types as specific probes applied on the strip. The line blot assays showed to be more appropriate for 
large scale HPV typing.  
The RFLP method enables HPV typing by the analysis of difference in DNA fragments length after 
cleavage of the consensus HPV amplicons with specific restriction endonucleases, while sequencing enables 
determination of all nucleotides alignment of the full PCR product length. Both methods are very 
informative but time consuming and inappropriate in case of multiple infections. Generally, they are used for 
research purpose rather than for routine clinical testing.  
In this study, we evaluated the consensus and TS-PCR, RFLP, sequencing and commercially 
available Line Probe HPV typing Assay (LiPA, Innogenetics) to determine the HPV types in cervical 
specimens.   
 
Material and Methods 
Study group 
We analysed 690 DNA from cervical scrapes of women with cytological diagnosis of High-grade 
Squamous Intraepithelial Lesions (HSIL)
16
 collected in different gynaecological clinics in Zagreb (Croatia). 
Cervical scrapes were collected with cyto-brushes, placed in 3-5 ml of phosphate-buffered saline (pH 7.2) 
and frozen at -20 C until analysis.  
 
DNA preparation 
              DNA from cervical cell samples was isolated as described previously.
17
 Briefly, cell suspensions 
were centrifuged (3,000 g, 10 min) and resuspended in lysis buffer (10 mM Tris-HCl; pH 7.5, 1 mM EDTA, 
pH 7.9; 0.5% SDS). Proteinase K (100 µg/ml) was added on pelleted cells and it was incubated overnight at 
37 C or 2h at 56 C. Standard NaCl or phenol-chloroform extraction and ethanol precipitation were used for 
DNA purification. The DNA precipitate was resuspended in 50-100 L of tridistillated sterile water. DNA 
concentration and the quality were determined both spectrophotometrically and by electrophoresis on 1% 
agarose gels.
18
  
Polymerase Chain Reaction (PCR) 
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 The amplification reactions included three sets of consensus primers: MY09/MY11, L1C1/L1C2-
1/L1C2-2 primers in a 2:1:1 ratio and GP5/6 consensus primers. TS primers for HPV 6/11, 16, 18, 31 and 33 
were also used in two separate multiplex PCR reactions, i.e. HPV 6/11 with 31 and HPV 16 and 18 with 
33.
8,19,20 
To control the quality of the isolated DNA and the absence of PCR inhibitors, we amplified the 268 
bp sequence of -globin gene using PC04/GH20 primers
21
 in a multiplex PCR with MY primers. Each 
amplification reaction was carried out in a total volume of 20 L. The reaction mixture contained 
tridistillated sterile water, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 100 M of each dNTP, 
0.15 M of each TS primer, 0.12 U AmpliTaq Gold DNA Polymerase (Roche) and 100 ng of each DNA. 
Each PCR was carried out with first denaturation step at 95 C for 10 min and final extension at 72 C for 15 
min. The conditions and the number of denaturation-annealing-extension cycles were different with each set 
of primers.
8
  
Aliquots of each PCR product (10 µl) were analysed by electrophoresis on 2% agarose gels stained 
with ethidium bromide. The amplified products were identified by UV irradiation of the gels and 
photographed by Image Master VDS (Pharmacia Biotech). 
Restriction Fragment Length Polymorphism (RFLP) 
A subset of samples, which remained untyped by TS-PCR were further analysed by restriction 
fragment length polymorphism (RFLP) as described previously.
22-24
 Briefly, an aliquot (4-12 μl) of an 
MY09/MY11 PCR product was used for each digestion. The restriction enzymes used for these analyses 
were DdeI, DraI, PstI, Sau3AI, BamHI, HaeIII and/or RsaI (Roche). RFLP can discriminate between 43 
HPV types and 2 subtypes (HPV 6b, 11, 13, 16, 18, 26, 30–35, 39, 40, 42–45, 51–59, 61, 62, 64, 66–73, 81–
84 and 89).
23
 Aliquots of PCR products were incubated at 37 C overnight with addition of 2-10 U of 
restriction enzyme and corresponding buffer
23
 and overlaid with mineral oil. Reactions were carried out in a 
total volume of 25 μl. Restriction fragments were analysed on 8% polyacrylamide gel during 3 h of 
electrophoresis at 500 V and stained with silver.
18
 They were also analysed on Spreadex EL 800 (Elchrom 
Scientific) gel during 150 min of electrophoresis at 120 V and 55 C and stained with SYBR Gold, according 
to manufacturer’s protocol (Molecular Probes, Eugene). The gels were photographed and analysed on Image 
Master VDS.   
Line Probe Assay (LiPA) 
The same subset of samples, which was analysed by RFLP was also tested with the commercially 
available HPV typing assay LiPA (Innogenetics).
25
 In this assay, 28 oligonucleotide probes that recognize 26 
different HPV types (6, 11, 16, 18, 31, 33–35, 39, 40, 42–45, 51–54, 56, 58, 59, 66, 68, 73, 70 and 74) were 
enzymatically tailed with poly (dT) and applied as horizontal lines to the nitrocellulose membrane strips. 
The PC04/GH20 primers for -globin gene were used for internal control, while SPF 10 primers were used 
for HPV DNA amplification. The PCR conditions were those recommended by manufacturer (Innogenetics). 
Amplified biotinylated SPF 10 PCR products were denatured under alkaline conditions and added to the 
strip in an appropriate hybridization buffer. After hybridization and stringent washing, the hybrids were 
detected by addition of a streptavidin-conjugate and a substrate, generating a purple precipitate at the probe 
line. The strip results were interpreted by comparing the hybridization pattern to the provided template.  
Sequencing 
A subset of HPV positive samples, which showed ambiguous result with either RFLP or LiPA, were 
amplified with MY09/MY11 primers and purified with QIAquick PCR Purification Kit (Qiagen) according 
to the manufacturer’s instructions. After purification, 2 μl of each amplicon was tested by electrophoresis on 
2% agarose gels for the evaluation of the quality and the quantity of amplified DNA. The purified amplicons 
were sequenced at the local core sequencing facility (ABI PRISM 310 Genetic Analyzer, Applied 
Biosystems) of Rudjer Boskovic Institute – Zagreb using the BigDye Terminator v1.1 Cycle Sequencing Kit 
(Applied Biosystems) and forward PCR primer. The resulting sequences were compared with HPV 
sequences of known types using the basic local alignment search tool from the NCBI website 
(www.ncbi.nlm.nih.gov/blast/Blast.cgi).
26
 
Statistical analysis 
The RFLP and LiPA assays were compared using unweighted Kappa statistic (MedCalc version 
7.3.0.1, MedCalc Software, Mariakerke, Belgium). A Kappa (K) value of 0 indicates no agreement better 
than chance and a value of 1 indicates perfect agreement. K values from 0 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 
0.61 to 0.80 and 0.81 to 1.00 indicate poor, fair, moderate, good and very good strength of agreement, 
respectively.  
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Results 
Detection and typing of common HPV types by consensus and TS-PCR  
 Each DNA specimen from cervical cell samples was positive for the -globin gene and as such 
suitable for further HPV DNA detection and typing by different methods.  
Out of 690 HSIL samples, 598 (86.7%) were HPV positive and 92 samples (13.3%) gave the 
negative result in PCR with consensus primers (MY09/MY11, L1C1/L1C2-1/L1C2-2 and/or GP5/6) and TS 
primers for HPV 6/11, 16, 18, 31 and 33 (Fig. 1). Out of HPV positive samples, 85.3% (510/598) were 
typed by TS-PCR being HPV 6/11, 16, 18, 31 and/or 33, while 14.7% (88/598) were not determined. The 
most prevalent HPV type in the study group was HPV 16, identified in 35.5% cases (245/690), while HPV 
31 was the second most frequent HPV type with a prevalence of 10.5% (72/690). They were followed by 
HPV types 6/11, 33 and 18 with a prevalence of 7.4% (51/690), 6.2% (43/690) and 4.9% (34/690), 
respectively. Multiple HPV infections with two or more HPV types (6/11, 16, 18, 31 and/or 33) were found 
in 9.4% (65/690) cases.  
Typing of rare HPV types by RFLP, LiPA and sequencing  
A subset of samples (88 out of 690) that were positive with consensus PCR but negative with TS-
PCR for HPV 6/11, 16, 18, 31 and 33 were further analysed with RFLP and LiPA, while 32 of them, for 
which  we could not determine the exact type with those methods, were additionally analysed by sequencing 
(Table 1). The combined results of HPV typing by RFLP, LiPA and sequencing are presented in Fig. 2. The 
most frequent low abundant HPV types in single infections were HPV 53, 58, 66, 56 and 52 found in 13.6% 
(12/88), 10.2% (9/88), 8% (7/88), 6.8% (6/88) and 4.5% (4/88) samples, respectively. Multiple HPV 
infections with two or more low abundant HPV types were found in 20.5% (18/88) cases. The most 
prevalent types in multiple infections were HPV 66, 51, 52 and 53 in 6.8% (6/88), 5.7% (5/88), 4.5% (4/88) 
and 4.5% (4/88) cases, respectively. Although rather frequently found in multiple infections, HPV 51 was 
not detected among single HPV infections. HPV type was not precisely determined in 3 specimens (3.4%). 
In two of those specimens sequencing detected a rare HPV isolate IS223, while RFLP and LiPA determined 
it as HPV 73. In one specimen sequencing detected a rare HPV isolate SDL105, while LiPA determined it as 
HPV 70 and RFLP failed to determine it (Table 1). 
Comparison of HPV typing by RFLP and LiPA 
Out of 88 samples analysed by RFLP and LiPA, single HPV infections were detected in 59 (67%) and 
57 (64.8%) cases by RFLP method and LiPA, respectively (Table 2). Multiple HPV infections were 
determined in 14.8% (13/88) by RFLP, and in 27.3% (24/88) by LiPA. In 18.2% (16/88) of cases RFLP 
method could not determinate any specific HPV type, while LiPA was not successful in typing 8% (7/88) 
cases.  
Inter-assay agreement (Kappa K ) was calculated with a 95% confidence interval (CI) for RFLP 
and LiPA assay pair for all HPV types detected by these two methods (Table 3). The perfect agreement 
between RFLP and LiPA assay pair was observed for HPV types 16, 18, 34 and 59 (K value of 1). For HPV 
types 53, 56 and 58 a very good strength of agreement (K ranging from 0.805 to 0.838) was observed. The 
inter-assay agreement for HPV 31 and 33 was good, with K values of 0.794 and 0.656, respectively.  HPV 
types 66 and 73 had moderate inter-assay agreement (K values of 0.453 and 0.542, respectively). A fair 
strength of inter-assay agreement was calculated for HPV types 39, 45, 52 and 68 (K ranging from 0.272 to 
0.389). For HPV types 26, 35, 40, 42, 51, 55, 61, 62, 64, 67, 70, 83 and 84, no agreement better than chance 
was observed (K value of 0).  
When we compared RFLP and LiPA according to the type of HPV and the number of identified HPV 
types, both in single and multiple infections, we found complete agreement between these two methods in 
38.6%, partial agreement in 20.5% and disagreement in 37.5% cases. For 3 samples (3.4%), it was not 
possible to compare these two methods (Table 1, Fig. 3).  
The main causes of disagreement between RFLP and LiPA findings are the following (a) RFLP could 
not determine HPV types determined by LiPA in 41.7% (15/36) cases, (b) both assays identified different 
HPV type in 19.4% (7/36) cases because the type detected by RFLP cannot be detected with LiPA and 
probably because RFLP is not sensitive enough to detect the other type detected by LiPA, and (c) RFLP 
could not resolve multiple HPV infections determined by LiPA in 16.7% (6/36) cases. The minor causes of 
disagreement between RFLP and LiPA consist of (a) RFLP detecting HPV types that LiPA a priori cannot 
detect (5.6%; 2/36), (b) HPV types determined by RFLP but not by LiPA even though it should (5.6%; 
2/36), (c) unresolved multiple HPV infections by RFLP and undetermined by LiPA (5.6%; 2/36), (d)  
different HPV type detected by these two methods (2.8%; 1/36), and (e) HPV type undetermined by both 
methods (2.8%; 1/36). 
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Comparison of sequencing with RFLP and LiPA results 
Out of 32 samples that were analysed by sequencing, 3 samples (9.4%) showed complete agreement 
in detecting single HPV type with both, RFLP and LiPA results, while partial agreement with both methods 
was found in 1 sample (3.1%) (Table 1). Complete agreement between RFLP and sequencing results was 
found in 14 samples (43.8%), while complete agreement between LiPA and sequencing was found in 5 cases 
(15.6%). Four samples showed complete disagreement of sequencing results in comparison with both, RFLP 
and LiPA (12.5%), one (3.1%) showed partial agreement with LiPA results, 3 of them (9.4%) were detected 
by sequencing as rare HPV isolates that could not be resolved by RFLP and/or LiPA and 1 sample (3.1%) 
was not determined by sequencing. 
 
Discussion 
This study was designed to detect and determine the most common and rare HPV types in HSIL 
samples by combining different methods: consensus and TS-PCR, RFLP, sequencing and a commercially 
available line probe HPV typing assay (LiPA, Innogenetics). The purpose of this study was also to evaluate 
the value of above listed different HPV typing methods and to identify the less common HPV types that 
might be of clinical significance in precancerous cervical lesions.   
Herein, 690 cervical specimens collected from Croatian women with HSIL diagnosis were analysed. 
Detection of HPV by consensus PCR found 86.7% HPV positive and 13.3% HPV negative samples. The 
high percentage of HPV positive HSIL samples was in line with the worldwide meta-analysis.
27,28
 Typing of 
the most common HPV types (HPV 6/11, 16, 18, 31 and 33) by TS-PCR  identified HPV 16, as the most 
prevalent type among Croatian women, and that was also found worldwide. The second most commonly 
found HR HPV type among Croatian women was HPV 31, which was also found on the second place in 
overall world HSIL cases. The following HPV types in this study in decreasing order were HPV 6/11, 33 
and 18, while in the worldwide meta-analysis those were HPV 58, 18 and 33; HPV 58 being very common 
type in Asia and South and Central America. The LR HPV 6/11 was frequently found in Croatian cervical 
HSIL samples, as well as HPV 6 was found in North America as a second most common HPV type among 
HSIL samples.
28
 
The multiple HPV infection, found in 9.4% cases by TS-PCR for HPV 6/11, 16, 18, 31 and 33, only, 
is probably underestimated because approximately 40 HPV types infect the anogenital tract. Indeed, multiple 
HPV infection in our study subset of 88 HSIL samples positive by consensus PCR and negative by TS-PCR 
for 6/11, 16, 18, 31 and 33 was found in higher percentage of 20.5% by combining methods: RFLP, LiPA 
and sequencing. This high percentage of multiple infections in HSIL was reported in previous studies.
29-32
  
Among the samples analysed by RFLP, LiPA and sequencing, the most frequent low abundant HPV 
types in single infections in decreasing order were HPV 53, 58, 66, 56 and 52. Similar frequencies of low 
abundant HPV types in HSIL samples were reported in previous studies.
32
 In case of multiple HPV 
infections with two or more low abundant HPV types, we found a slightly different situation. The most 
prevalent types in multiple infections were HPV 66, 51, 52 and 53. Interestingly, rather frequently found in 
multiple infections, mostly identified by LiPA, HPV 51 was rarely detected as single HPV infection, also 
exclusively by LiPA method. Moreover, in two samples where LiPA found single infection with HPV 51, 
RFLP and sequencing, both, identified other HPV types, i.e. HPV 61 in one case and HPV 62 in other 
(Table 1). The question could be raised: are these positive findings by LiPA really HPV 51 or they are 
results of possible cross-hybridization with other HPV types present in multiple infections. However, HPV 
51 was also frequently found in other studies in which other line blot assays for HPV typing
29-32 
were used, 
which indicate that it can be considered as common HPV type, especially in HSIL specimens.  
Combining RFLP, LiPA and sequencing, 3 specimens remained with uncertain HPV type. In two of 
those specimens sequencing detected a rare HPV isolate IS223, while RFLP and LiPA determined it as HPV 
73. Perhaps the IS223 isolate is very close to HPV type 73. In another of those specimens sequencing 
detected a rare HPV isolate SDL105, while LiPA determined it as HPV 70 and RFLP failed to determine it 
as any HPV type. This finding is also suggesting that the SDL105 isolate is very close to HPV type 70.
4  
When we compared only RFLP and LiPA, we found that while both methods showed rather similar 
frequencies in determination of single HPV infections (67% versus 64.8%, respectively), LiPA detected 
multiple infections almost twice more often than RFLP (27.3% versus 14.8%, respectively). The fact is that 
RFLP is not a method of choice for detection of multiple HPV infections, contrary to LiPA.  
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Inter-assay agreement (Table 3) for RFLP and LiPA assay pair for each HPV type detected by these two 
methods indicate perfect agreement for HPV types 16, 18, 34 and 59 (K value of 1), signifying that these 
types were almost equally detected by both methods. This finding is encouraging since HPV 16, 18 and 59 
belong to HR HPV types of which HPV 16 and 18 are the most frequently found types in HSIL samples and 
in cervical cancer worldwide.
27,28 
For HPV types 53, 56 and 58 a very good strength of agreement (K 
ranging from 0.805 to 0.838) was observed, which is also very good result since HPV 56 and 58 are HR and 
HPV 53 probably HR. The inter-assay agreement for HR HPV 31 and 33 was good, with K values of 0.794 
and 0.656, respectively. The subset of samples subjected to inter-assay analysis was a priori depleted of 
HPV 31 and 33, so the K values in these cases are not representative as it is referring to a low number of 
positive samples. HPV types 66 and 73 had moderate inter-assay agreement (K values of 0.453 and 0.542, 
respectively), although each of them can be identified by both methods. Herein, either RFLP underestimates 
the presence of HPV 66 and 73 or LiPA overestimated it. Unfortunately, a fair strength of inter-assay 
agreement was calculated for HPV types 39, 45, 52 and 68 (K ranging from 0.272 to 0.389), which are 
relatively frequently found in this study group (Fig. 2). In this case also, either RFLP underestimates the 
presence of these types or LiPA overestimated it. For HPV types 26, 35, 40, 42, 51, 55, 61, 62, 64, 67, 70, 
83 and 84 no agreement better than chance (K value of 0) was observed, probably because of the low 
number of cases positive for each of these types, except for HPV 51, which was found in a high proportion 
in multiple HPV infections by LiPA. Some of the observed discrepancies can be attributed to different 
sensitivity of consensus primers used, i.e. generating amplicons of different size; from our previous 
observational study comparing different consensus HPV primers shorter PCR products were more efficiently 
amplified.
20
 Because of these important discrepancies between RFLP and LiPA (Fig. 3) for the detection of, 
especially, HPV types 39, 45, 51, 52, 66, 68 and 73, the evaluation of the findings by RFLP and LiPA, with 
a third typing method would be appropriate. Neither of those HPV typing assays is perfect, mainly because 
RFLP could not identify HPV types determined by LiPA (41.7% cases), RFLP identified different HPV 
types, which are untypable by LiPA (19.4% cases), and RFLP could not resolve multiple HPV infections 
determined by LiPA (16.7% cases). TS-PCR for each of HPV types might be time-consuming, and 
sequencing inappropriate because most of these types were found as multiple HPV infections. Thus, similar 
line blot assays like LiPA would be more eligible for the confirmation of HPV typing findings.
32 
A subset of 32 samples was additionally analysed by sequencing, after we could not determine the 
exact type by comparing RFLP and LiPA results. Three samples, in which HPV 31, 52 and 66 were 
determined by sequencing showed complete agreement with both, RFLP and LiPA. However, LiPA 
identified more types in two of those samples, besides HPV 52 and 66 what was the reason for the additional 
analysis of these samples by sequencing. Partial agreement of sequencing findings with both, RFLP and 
LiPA results was found in one sample, where sequencing detected HPV 66, while both, RFLP and LiPA 
detected multiple infections with HPV types 18 and 66. A priori multiple HPV infections could not be 
resolved by sequencing, thus we can consider this case as an exception to the rule. In cases of multiple HPV 
infections, RFLP method can be more informative than sequencing, but LiPA is the best choice among those 
three methods for the simultaneous identification of HPV types.  
This study emphasizes the value of different methods of HPV detection and typing. At the moment 
there is no gold standard for HPV typing. Clinical laboratories, that intend to adopt the HPV typing, should 
consider the advantages and disadvantages of each of the described method. From the results of this study 
we can suggest to precede with typing by TS-PCR of the most commonly expected HPV types in the studied 
population; in Croatia they are LR HPV 6/11 and HR HPV 16, 18, 31, 33 and probably HPV 51, 53, 56, 58 
and 66 to be confirmed on a larger study group. Confirmation of single HPV infection can be made by 
sequencing, if available, rather than RFLP that is cumbersome and time-consuming. The commercially 
available LiPA (Innogenetics) gives a wide spread of HPV types in one sample, it is suitable for the 
identification of multiple HPV infection besides single HPV infections and it is easy to perform but it’s 
major limitation is the price of the test. Moreover, the high degree of discordant findings between HPV 
typing tests in this study indicates that neither test is perfect. Thus, careful consideration should be taken 
when test are used for clinical purpose.   
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Figure 1. Prevalence of common human papillomavirus (HPV) types in high-grade squamous intraepithelial 
lesions (HSIL) samples obtained by polymerase chain reaction (PCR) with consensus primers (MY09/MY11, 
L1C1/L1C2-1/L1C2-2 and/or GP5/6) and type-specific primers (TS) for HPV 6/11, 16, 18, 31 and 33  
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Table 1. HPV genotyping by RFLP, LiPA and sequencing 
Number of 
cases  
RFLP 
(N=88) 
LiPA 
(N=88) 
Sequencing 
(N=32) 
2 16 16 / 
1 31 31 / 
1 31 31 31 
1 33 53 33 
1 33 33 / 
1 33 ND 33 
1 34 34/51/52 / 
1 39 39/51 / 
1 45 or 56 45/52 45 
1 ND 45 45 
2 ND 52 52 
1 52 52/68 or 73 52 
1 52 52 / 
10 53 53 / 
2 53 52/53 / 
5 56 56 / 
1 ND ND 56 
7 58 58 / 
1 ND 58 58 
1 58 52/58 / 
3 59 59 / 
1 61 51 61 
1 61 52 61 
1 61 53 61 
1 26 or 62 51 62 
3 ND 66 66 
1 66 52/66 66 
2 66 66 / 
1 66 66/70* / 
1 67 ND 67 
2 68 68 or 73 / 
1 ND 51/70 70 
1 ND 70 70 
1 73 68 or 73 73 
1 26 or 62 52 81 
1 83 ND 83 
1 84 42 84 
1 ND 66 84 
1 64 or 84 66 84 
1 18/66 18/66 66 
1 ND 52/56/66 ND 
1 ND 45 82 
1 ND 45 / 
1 33/59 33/59/39/52 / 
1 58 58/51/68 or 73 / 
1 55/58 ND / 
1 Multiple 39/51/70 / 
1 52/61 39/52 / 
1 Multiple 66/68 or 73 / 
1 53/73  53/68 Multiple 
1 Multiple 51/53/68 or 73 / 
1 Multiple ND / 
1 Multiple ND Multiple 
1 Multiple 51/52/66 / 
1 Multiple 35/53/66 / 
1 Multiple 31/40/58/53 / 
1 ND 39/51/66 / 
1 73 39/68 or 73 IS223 
1 ND 70 SDL105 
1 73 68 or 73 IS223 
               ND – not determined; *HPV 70, very weak signal 
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Table 2. Detection of HPV infections by RFLP and LiPA assays  
Type of HPV 
infection (N=88) 
RFLP 
No. (%) 
LiPA 
No. (%) 
Single 59 (67.0) 57 (64.8) 
Multiple 13 (14.8) 24 (27.3) 
Undetermined 16 (18.2) 7 (8.0) 
 
 
 
 
 
 
 
Figure 2. Frequencies of low abundant human papillomavirus (HPV) types in the subset (N=88) of  high-
grade squamous intraepithelial lesions (HSIL) samples positive by consensus PCR and negative by TS-PCR 
for 6/11, 16, 18, 31 and 33, obtained by combining results of restriction fragment length polymorphism 
(RFLP) analysis, line probe assay (LiPA, Innogenetics) and sequencing; *incompletely determined HPV 
type   
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Table 3. Identification of a particular HPV type either by RFLP or LiPA and agreement between these 
two assays given as Kappa values 
HPV type RFLP LiPA Kappa 95% CI 
16 2 2 1.000 1.000 to 1.000 
18 1 1 1.000 1.000 to 1.000 
26* 2 0 0.000 -1.370 to 1.370 
31 2 3 0.794 0.394 to 1.195 
33 4 2 0.656 0.185 to 1.127 
34 1 1 1.000 1.000 to 1.000 
35 0 1 0.000 -1.949 to 1.949 
39 1 6 0.272 -0.349 to 0.892 
40 0 1 0.000 -1.949 to 1.949 
42 0 1 0.000 -1.949 to 1.949 
45 1 4 0.389 -0.291 to 1.069 
51 0 10 0.000 -0.584 to 0.584 
52 3 16 0.274 -0.090 to 0.638 
53 13 18 0.805 0.640 to 0.971 
55* 1 0 0.000 -1.949 to 1.949 
56 6 6 0.821 0.576 to 1.066 
58 10 11 0.838 0.657 to 1.018 
59 4 4 1.000 1.000 to 1.000 
61* 4 0 0.000 -0.957 to 0.957 
62* 2 0 0.000 -1.370 to 1.370 
64* 1 0 0.000 -1.949 to 1.949 
66 5 15 0.453 0.134 to 0.772 
67* 1 0 0.000 -1.949 to 1.949 
68 2 10 0.307 -0.151 to 0.765 
70 0 5 0.000 -0.851 to 0.851 
73 4 10 0.542 0.188 to 0.896 
83* 1 0 0.000 -1.949 to 1.949 
84* 2 0 0.000 -1.370 to 1.370 
*HPV types that LiPA cannot detect 
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Figure 3. Comparison of HPV typing by RFLP and LiPA (N=88) 
 
